HDHarjot Singh Dhaliwal

Harjot Singh Dhaliwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Harjot Singh Dhaliwal has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Global Pharmaceutical Regulation: Comparative Frameworks and Operations

    by Omolayo Tinuke Umaru, Adebowale Sylvester Adeyemi, Olajumoke Aderonmu, Balyodh Singh Bhangu, Harjot Singh Dhaliwal, Hae Lim, Taiwo Opeyemi Aremu

    Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.


  • Open Access

    Global Pharmaceutical Regulation: Comparative Frameworks and Operations

    by Omolayo Tinuke Umaru, Adebowale Sylvester Adeyemi, Olajumoke Aderonmu, Balyodh Singh Bhangu, Harjot Singh Dhaliwal, Hae Lim, Taiwo Opeyemi Aremu

    Pharmaceutical regulation and healthcare governmental agencies are central to protecting public health by governing clinical trials, market authorization, and post-market safety monitoring of medicinal products worldwide. Although substantial literature describes major established systems, particularly the United States Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the European Union regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analysis that integrate both established and emerging regulatory authorities remain limited. This review examines the core functions of regulatory affairs across the product life cycle and compares key features of global regulatory frameworks, including approval pathways, evidentiary expectations, data transparency, and pharmacovigilance approaches. It emphasizes the need for systems thinking to balance innovation with safety, efficacy, and quality, while anticipating unintended consequences of new therapies. This evaluation also highlights how region‑specific constraints and enabling infrastructures, such as national drug‑utilization registries in parts of Europe, can shape regulatory decision‑making and post‑market evaluation. Finally, this paper discusses opportunities for stronger international alliances and greater harmonization to improve efficiency, support timely patient access to essential therapies, strengthen risk management, and reinforce global health security in an increasingly interconnected healthcare environment.